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Arjuna is a potential cardioprotective agent belonging to the 
Combretaceae family. It is an ayurvedic remedy that has been 
mentioned since vedic period in many ancient Indian medicinal 
texts including Charaka Samhita, Sushruta Samhita, and Astang 
Hridayam. It was Vagabhatta who, for the first time, advocated 
the use of stem bark powder in heart ailments.[1]
ETHNOMEDICAL USES
The bark has been described as an astringent, demulcent, 
expectorant, cardiotonic, styptic, antidysenteric, urinary astrin‑
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ABSTRACT
Terminalia arjuna, commonly known as arjuna, belongs to the family of Combretaceae. Its bark decoction is being used in the Indian 
subcontinent for anginal pain, hypertension, congestive heart failure, and dyslipidemia, based on the observations of ancient physicians 
for centuries. The utility of arjuna in various cardiovascular diseases needs to be studied further. Therefore, the present review is an 
effort to give a detailed survey of the literature summarizing the experimental and clinical studies pertinent to arjuna in cardiovascular 
disorders, which were particularly performed during the last decade. Systematic reviews, meta‑analyses, and clinical studies of arjuna 
were retrieved through the use of PubMed, Google Scholar, and Cochrane databases. Most of the studies, both experimental and 
clinical, have suggested that the crude drug possesses anti‑ischemic, antioxidant, hypolipidemic, and antiatherogenic activities. Its 
useful phytoconstituents are: Triterpenoids, β‑sitosterol, flavonoids, and glycosides. Triterpenoids and flavonoids are considered to be 
responsible for its beneficial antioxidant cardiovascular properties. The drug has shown promising effect on ischemic cardiomyopathy. 
So far, no serious side effects have been reported with arjuna therapy. However, its long‑term safety still remains to be elucidated. 
Though it has been found quite useful in angina pectoris, mild hypertension, and dyslipidemia, its exact role in primary/secondary 
coronary prevention is yet to be explored.
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gent, and has shown to be useful in fracture, ulcers, leukorrhea, 
diabetes, anemia, cardiopathy, and cirrhosis.[2] Chakradatta, 
the great ancient physician, recommended it to be given as a 
decoction of bark with milk or as a ghrita (a preparation with 
ghee or butter).[3] Decoction of the bark has been used as ulcer 
wash, while bark ashes have been prescribed for snakebite 
and scorpion sting.[4] Traditional healers from Kancheepuram 
district, Tamil Nadu boil the bark powder with water, and 
inhale it to cure headache and to kill worms in teeth. They 
also use fruit paste topically on wounds.[5] Fresh leaf juice is 
used for the treatment of earache and bark powder for treating 
heart ailments by Malabar tribe, Kerala.[6] Tribals living in 
Sundargarh District, Orissa use dried bark powder along with 
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rice washed water to treat blood in urine, and tribes living in 
Malkangiri district chew the fresh bark and swallow the juice 
as an antacid.[7,8]
HABITAT
Arjuna tree is about 60‑80 ft in height, and is seen along rivers, 
streams, and dry water bodies throughout the Indo‑sub‑Himalayan 
tracts of Uttar Pradesh, southern Bihar, Chota Nagpur, Burma, 
Madhya Pradesh, Delhi, and Deccan region [Figure 1]. It is also 
found in the forests of Sri Lanka and Mauritius.[3,9] It grows almost 
in all types of soils, but prefers humid, fertile loam and red lateritic 
soils. It can tolerate half submergence for a few weeks. Arjuna is 
propagated by seeds; Germination takes 50‑70 days with 50‑60% 
germination.[10]
PHARMACOGNOSTIC FEATURES
The outer surface of the bark is smooth, while the inner surface 
has longitudinal striation and is pinkish in color.[2] The bark gets 
flaked off itself in the month of April–May [Figure 2].[11]
On microscopic examination of  the mature bark, a cork consist‑
ing of 9‑10 layers of tangentially elongated cells, 2‑4 cells thick 
phellogen, and phelloderm consisting of tangentially elongated 
cells are seen. The phloem is broad, consisting of ceratenchyma, 
phloem parenchyma, phloem fibers, and crystal fibers with rosette 
crystals of calcium oxalate. Periderm and secondary phloem are 
present in the old bark.[9,11, 12]
Leaves are sub‑opposite, coriaceous, oblong/elliptic, dull green 
from the upper side and pale brown on the lower side, often unequal 
sided with 10‑15 pairs of nerves [Figure 3]. Flowers are white 
in color and bisexual, arranged in spikes with linear bracteoles 
[Figure 4]. Fruits are ovoid/oblong with 5‑7 hard angles or wings. 
The lines on wings are oblique and curving upward [Figure 5].[2]
Major chemical constituents of arjuna have been shown in 
Table 1.[9,13‑17]
Various extracts of the stem bark of arjuna have shown to 
possess many pharmacological properties including inotropic, 
anti‑ischemic, antioxidant, blood pressure lowering, antiplatelet, 
hypolipidemic, antiatherogenic, and antihypertrophic.[18] Thus, 
in the present article, we have made an attempt to review and 
give up‑to‑date information pertinent to the usage of arjuna as a 
potential cardioprotective agent.
EXPERIMENTAL STUDIES
Effects on cardiac hemodynamics, coronary flow, and blood 
pressure
Bark stem of arjuna possesses diuretic, inotropic, and chrono‑
tropic properties.[9] In the Langendorff’s rabbit heart preparation, 
the aqueous extract has demonstrated to cause an increase in the 
coronary flow.[19] Substantiating the earlier findings recently, an 
experimental study showed that the aqueous extract of arjuna 
increased the force of contraction of cardiac muscle in frog’s heart 
in situ, hypodynamic frog’s heart in situ, and isolated perfused 
rabbit heart. It increased the coronary flow in isolated perfused 
Figure 1. Terminalia arjuna tree
Figure 2. Bark stem of Terminalia arjuna
Figure 3. Leaves of Terminalia arjuna
rabbit heart and produced bradycardia.[20] The inotropic effect is 
considered to be mediated through the high concentration of Ca++ 
present in the plant.[21]
Aqueous and alcoholic bark extract, when given intrave‑
nously, intracerebrally, and intravertebrally in dog, resulted in a 
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Figure 4. Flower of Terminalia arjuna Figure 5. Fruits of Terminalia arjuna (ripe, fresh)
Table 1. Major chemical constituents of arjuna
Part of plant Major chemical constituents Major chemical constituents
Stem bark Triterpenoids Arjunin, arjunic acid, arjunolic acid, arjungenin, terminic acid, ajunglucosides 
IV and V, arjunasides A‑E, 2‑alpha, 3‑beta‑dihydroxyurs‑12,18‑dien‑28‑oic acid 
28‑O‑beta‑d‑glucopyranosyl ester
Glycosides Arjunetin, arjunoside I, arjunoside II, arjunaphthanoloside, terminoside A
Flavonoids Arjunolone, arjunone, baicalein, luteolin, gallic acid, ethyl gallate, quercetin, kempferol, 
pelargonidin, oligomeric proanthocyanidins
Tannins Pyrocatechols, punicallin, punicalagin, terchebulin, terflavin C, castalagin, casuariin, casuarinin
β‑sitosterol
Minerals/trace elements Calcium, aluminum, magnesium, silica, zinc, copper
Roots Triterpenoids Arjunic acid, arjunolic acid, oleanolic acid, terminic acid












Seeds Cardenolide 14,16‑dianhydrogitoxigenin‑3‑beta‑d‑xylopyranosyl (1‑‑>2)‑O‑beta‑d‑galactopyranoside
dose‑dependent decrease in blood pressure.[9] Singh et al. reported 
that an aqueous solution of 70% alcoholic bark extract produced 
dose‑dependent decrease in heart rate and blood pressure in dogs, 
though the mechanism was not determined.[22]
Takahashi et al. demonstrated that the hypotensive effect of 
arjuna was observed with a fraction containing tannin‑related 
compounds separated from the aqueous extract, which was not 
affected by pretreatment of rats with propranolol, but was at‑
tenuated by pretreatment with atropine. This suggested that the 
hypotensive effect may be mediated by cholinergic mechanisms.[23] 
Later on, it was documented that the 70% alcoholic extract pro‑
duced dose‑dependent hypotension of peripheral origin which 
might be due to adrenergic β2‑receptor agonistic and/or direct 
action on the heart muscle. It was also suggested that muscarinic 
or histaminergic mechanisms are not likely to be involved in the 
hypotension produced.[24]
In a recent study, it has been established that the method of 
administration and/or selective omission of the hydrophobic com‑
ponents from the bark powder could be crucial to the efficacy and 
safety of arjuna bark in cardiac therapy.[25]
Antioxidant and cardioprotective effect
Dried, pulverized bark has been shown to augment endogenous 
antioxidant compounds of rat heart and prevent oxidative stress 
associated with ischemic–reperfusion injury of the heart.[26]
It was suggested that the alcoholic extract of arjuna in rabbit 
induces myocardial heat shock protein 72 and augments myocar‑
dial endogenous antioxidants which offer cardioprotection against 
oxidative stress associated with myocardial ischemic–reperfusion 
injury.[27] The cardioprotective effect of the active phytocon‑
stituents of arjuna bark against carbon tetrachloride and sodium 
fluoride induced oxidative stress, probably via its antioxidant 
properties, has also been documented. In the above models, ferric 
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reducing/antioxidant power assay revealed that ethanol extract 
enhanced the cardiac intracellular antioxidant activity.[28,29] In a 
recent study, the methanol extract yielded the highest phenolic 
and flavonoid content and was found to possess the highest total 
antioxidant capacity. Thus, it can be inferred that there exists a 
linear correlation between the antioxidant capacity and the total 
phenolic content of the extracts.[30] In another study, both alco‑
holic and aqueous extracts of the bark attenuated H2O2‑mediated 
reactive oxygen species generation in human monocytic cells by 
promoting catalase and glutathione peroxidase (GPO) activities 
and by sustaining cellular reducing power. Moreover, the extracts 
inhibited lipid peroxidation (LPO) and 3‑hydroxy‑3‑methyl‑gluta‑
ryl‑CoA (HMG‑CoA) reductase, but had no effect on lipoprotein 
lipase.[31]
In isoprenaline‑induced myocardial ischemia (MI), arjuna has 
been found to possess prostaglandin E2‑like activity with coronary 
vasodilatation and hypotension.[1] The bark extract has shown to 
significantly prevent isoprenaline‑induced increase in oxidative 
stress and decline in endogenous antioxidant level.
Arjunolic acid has been found to prevent the decrease in the 
levels of superoxide dismutase, catalase, GPO, ceruloplasmin, 
α‑tocopherol, reduced glutathione, ascorbic acid, lipid peroxide, 
and myeloperoxidase.[32]
Further, the bark extract has also shown protective effects 
against doxorubicin‑induced DNA damage and cardiotoxicity.[33,34] 
Kumar et al. demonstrated that arjuna protects the heart against 
myocardial changes induced by chronic β‑adrenoceptor stimula‑
tion.[35] Substantiating this, in a recent experiment, the bark extract 
significantly attenuated cardiac dysfunction and myocardial injury 
in rats with congestive heart failure (CHF). Cardioprotective ac‑
tion of arjuna was comparable to fluvastatin. Arjuna bark extract 
has a significant prophylactic and therapeutic beneficial effect in 
protecting heart against catecholamine‑induced CHF, possibly 
through maintaining endogenous antioxidant  enzyme activities 
and inhibiting LPO and cytokine levels.[36]
Recently, Mythili et al. confirmed the earlier findings that 
triterpenoids derived from arjuna extract containing arjunolic acid 
show cardioprotective activity by boosting endogenous antioxidant 
defense system.[37]
Hypolipidemic and antiatherogenic activity
Earlier animal experiments have demonstrated that arjuna bark 
powder/extract reduces the total cholesterol (TC) and triglycer‑
ide (TG) levels.[38‑41] On comparing the hypolipidemic property 
of the bark in different solvent fractions (petroleum ether, solvent 
ether, ethanol, and water) in hyperlipidemic rats, it was observed 
that only the ethanolic fraction exerted significant lipid‑lowering 
effect. Solvent ether and ethanolic fractions caused a decrease in 
the plasma levels of lipids in triton as well as in high fat diet (HFD) 
fed models of hyperlipidemia in hamsters. In an in vitro experi‑
ment with arjuna fractions at concentrations of 50‑500 µg/ml, they 
were found to inhibit the oxidative degradation of lipids induced 
by metal ions in human low density lipoprotein (LDL) and rat 
liver microsomes. When these fractions were tested against the 
generation of oxygen free radicals, they counteracted the forma‑
tion of superoxide anions and hydroxyl radicals in nonenzymic 
test systems. The efficacy of arjuna fractions was found to be in 
the order: Ethanol fraction > solvent ether fraction > petroleum 
ether fraction.[42]
The ethanolic fraction possesses potent antioxidant and hy‑
polipidemic properties compared to other fractions, and this has 
been substantiated by other studies also.[43,44] Subsequent work 
done by Sharma et al. also substantiated the hypolipidemic and 
antioxidant effect of arjuna. In addition to this, they also found 
that recipes (Arjuna Omelette and Arjuna En Upma) incorporating 
arjuna bark showed good acceptability, meriting their inclusion 
in the daily diet of the people needing long‑term intervention for 
elevated lipids and oxidative stress levels.[45]
The hypolipidemic action is thought to be mediated through 
increased hepatic clearance of cholesterol, down‑regulation of 
lipogenic enzymes, and inhibition of HMG‑CoA reductase.[46] 
Further, Parmar et al. showed that there is a possibility of involve‑
ment of thyroid hormones (suppression of thyroid function) in 




The anti‑ischemic effect of bark powder was evaluated in 
30 patients of stable angina/post‑infarct angina (500 mg tds). 
The authors observed that the mean anginal frequency decreased 
significantly, along with a significant decrease in systolic blood 
pressure (SBP), improvement in ECG changes, and reduction in 
plasma cortisol and serum cholesterol levels.[48]
Later, in a study, 500 mg of bark powder was administered 
twice daily to 25 coronary artery disease (CAD) patients for 
3 months. A reduction in the grade of positivity of treadmill 
test (TMT) response was observed in six patients, in addition to 
improvement in exerc ise tolerance and a reduction in the frequency 
of anginal attacks and use of sublingual nitrates.[49]
Subsequently, in an open‑label trial, it was demonstrated 
that there was a 50% reduction in angina episodes along with a 
significant delay in the time to the onset of angina on TMT and 
appearance of ST–T changes in ECG after arjuna therapy was 
administered in stable angina patients. Significant lowering of 
SBP and body mass index, with a marginal improvement in left 
ventricular ejection fraction (LVEF) and a slight increase in high 
density lipoprotein (HDL) levels were also observed. In unstable 
angina patients, there was an insignificant reduction in anginal 
frequency. These results suggest that monotherapy with arjuna 
is fairly effective in patients with stable angina, but has a limited 
role in unstable angina.[50]
In yet another study, 500 mg of bark powder was admin‑
istered 8 hourly to 10 patients of post‑myocardial infarction 
angina and 2 patients of ischemic cardiomyopathy for a period of 
3 months. These patients were compared with matched patients 
of post‑myocardial infarction angina receiving only conventional 
treatment. Significant reduction in anginal frequency, improvement 
in LVEF (from 42.25 ± 9.96% to 52.57 ± 12.32%), and reduc‑
tion in left ventricular mass (LVM; from 159.18 ± 51.11 g/m2 to 
140.62 ± 55.65 g/m2) was noted.[51]
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The efficacy of Hartone (an herbal product containing arjuna) 
was studied in 10 stable angina patients. The results were compared 
with those of 10 patients of stable angina on 20 mg of isosorbide 
mononitrate (ISMN) administered twice daily. It was observed that 
Hartone gave symptomatic relief in 80% of patients as compared 
to 70% in ISMN alone group. In addition, arjuna was better toler-
ated than ISMN.[52]
In a randomized, double‑blind, cross‑over study, 58 male 
patients with chronic stable angina (class II–III) with evidence of 
provocable ische mia on TMT received 500 mg of 90% alcohol 
extract 8 hourly, ISMN (40 mg/day), or a matching placebo for 
1 week each after a washout period of at least 3 days. It was found 
that arjuna therapy was associated with a significant decrease in 
the frequency of angina and the need for isosorbide dinitrate. Im-
provements in clinical and TMT parameters were observed with 
both arjuna and ISMN as compared to placebo. No significant 
differences were observed in the above parameters when arjuna 
and ISMN therapies were compared.[53]
CHF/hypertension
In one of the earliest studies, 10 patients with CHF received 4 
g of arjuna bark powder twice daily for 1 month. The researchers 
observed improvement in the functional class,  breathlessness, 
and overall well‑being with significant diuresis, and a fall in both 
systolic and diastolic blood pressure.[54]
Subsequently, the effect of bark extract (500 mg 8 hourly) 
was studied in a double‑blind placebo‑controlled two‑phase trial 
comprising 12 patients with refractory CHF. In the first phase, 
arjuna was administered for a period of 2 weeks. A decrease in 
echo‑left ventricular end‑diastolic and end‑systolic volume indices, 
an increase in left ventricular stroke volume index, and an increase 
in LVEF were recorded suggesting improvement. On long‑term 
evaluation (20‑28 months), in addition to continued improvement 
in symptoms and signs, they also reported an improvement in 
quality of life.[55]
A study done with abana (herbal formulation containing 
arjuna) in hypertensive individuals revealed an improvement in 
cardiac function as indicated by an increase in ejection fraction 
and a significant reduction of the SBP, echocardiographic left 
ventricular internal diameter, posterior wall thickness, and inter-
ventricular septal thickness.[56]
Recently, arjuna has also been shown useful in improving 
cardiovascular endurance and in lowering SBP in normal healthy 
subjects.[57]
Rheumatic heart disease
Efficacy of arjuna in decompensated rheumatic heart dis-
ease was studied in a double‑blind study in which 30 patients of 
rheumatic valvular heart disease with CHF were administered 
200 mg arjuna thrice daily. The results revealed a significant 
improvement in LVEF, exercise duration, and significant reduc-
tion in heart size.[58]
Ischemic mitral regurgitation
In a randomized, double‑blind, placebo‑controlled study done 
in patients with ischemic mitral regurgitation (IMR) following 
acute myocardial infarction, arjuna was found to significantly 
decrease IMR and anginal frequency. In addition, there was also 
significant improvement in diastolic dysfunction (E/A ratio; from 
0.93 ± 0.31 to 1.38 ± 0.40 at 12 weeks).[59]
Cardiomyopathy
In addition to its anti‑ischemic property, arjuna was found to 
reduce LVM and improve LVEF.[59] A recent observational study 
revealed that when patients of dilated cardiomyopathy with re-
duced LVEF received arjuna in addition to their standard therapy, 
there was a significant improvement in left ventricular parameters 
as well as functional capacity.[60]
Platelet aggregation
The bark extract has been found to decrease platelet activation 
and possess antithrombotic properties in vitro in 20 patients of 
angiographically proven CAD and 20 age‑ and sex‑matched con-
trols. The possible mechanism could be by desensitizing platelets 
by competing with platelet receptor or by interfering with signal 
transduction.[61]
In another recent randomized, double‑blind, parallel‑group, 
placebo‑controlled study in patients with type 2 diabetes mel-
litus, 500 mg of arjuna administered thrice daily resulted in a 
significant increase in mean cardiac output from 4.34 ± 0.38 
to 4.86 ± 0.20 (l/min). In addition to this, there was a reduc-
tion in mean systemic vascular resistance from 1729 ± 93.52 
to 1484 ± 115.5 ( dyne sec/cm5). Arjuna also caused significant 
inhibition of platelet aggregation.[62]
Oxidative stress/dyslipidemia
In a study on 21 patients with coronary heart disease 
administered 1 g of bark powder twice daily with milk for 
4 months, the patients showed improvement in lipid profile. In 
addition to this, patients got symptomatic relief after 1 month 
of treatment.[63]
Antioxidant effect of bark powder (500 mg) has been demon-
strated to be comparable to vitamin E (400 IU) in a randomized, 
controlled, open trial done in 105 patients with coronary heart 
disease. The authors also observed a significant decrease in TC, 
LDL, and lipid peroxide levels. The hypocholesterolemic effect 
was attributed to the soluble fibers and sitostanol content, while 
the antioxidant effect was attributed to the flavonoids.[64] Further, 
it was observed in a study that when the bark powder was given 
along with statin for 3 months, it resulted in 15% reduction in TC, 
11% reduction in TG, and 16% reduction in LDL, while there was 
minimal decline in lipoprotein (a) and nitrite levels.[65]
In a prospective cohort study, dyslipidemic patients received 
arjuna powder (5 g, BD) for 3 weeks followed by Arogyavardhini 
Vati (500 mg, BD) for 4 weeks. A significant reduction in TC, 
LDL, TG, serum C‑reactive protein, blood glucose, and an increase 
in HDL level were found, which supported the role of arjuna in 
dyslipidemic patients.[66]
Lipoprotein(a)
A significant reduction in lipoprotein(a) levels amounting to 
24.71% following the administration of arjuna in a patient of 
β‑thalassemia associated with hyperlipoproteinemia and metabolic 
syndrome has been reported.[67]
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Endothelial dysfunction
In a double‑blind, placebo‑controlled, cross‑over study involv‑
ing 18 healthy male smokers and an equal number of age‑matched 
non‑smoker controls, it was observed that the hydroalcoholic ex‑
tract of bark when given for 2 weeks led to significant regression 
of the endothelial abnormality amongst smokers.[68]
Thrombotic condition
In a recent study done to investigate the in vitro throm‑
bolytic and membrane‑stabilizing action of four Bangladeshi 
medicinal plants including arjuna, the methanol extract was 
found to possess significant thrombolytic activity (30.57%). It 
also significantly inhibited the hemolysis of RBCs in both hy‑
potonic solution and heat‑induced conditions. This showed that 
it has moderate thrombolytic activity; however, more research 
is needed to isolate the secondary metabolites responsible for 
the activity.[69]
Not much data is available to comment on the effect of arjuna 
on cytochrome P450 (CYP450) enzyme. Results from a recent 
in vitro study indicate that arjuna extracts contain constituents 
that can potently inhibit the activity of CYP1A.[70]
TOXICITY AND SIDE EFFECTS
Mild side effects like nausea, gastritis, headache, bodyache, 
constipation, and insomnia have been reported. No hematologi‑
cal, renal, or metabolic toxicity has been reported even after 
more than 24 months of its administration.[48,50,53,55] However, 
Parmar et al. noticed that administration of arjuna resulted 
in reduction of thyroid hormone concentration in euthyroid 
animals, whereas the hepatic LPO was increased. Thus, high 
amounts of the plant extract should not be consumed, as it may 
induce hepatotoxicity as well as hypothyroidism.[47] The results 
from a recent acute and oral toxicological study done in animals 
showed that administration of ethanolic extract at a limit dose 
of 2000 mg/kg orally did not produce any kind of toxicity and 
death in animals.[46]
CONCLUSION
The eternal interest in medicinal plants has led to the dis‑
covery of new chemical constituents and pharmacological ac‑
tions of arjuna. Its efficacy as an anti‑ischemic agent, a potent 
antioxidant, and an antiatherogenic agent has been amply dem‑
onstrated in various experimental and clinical studies. However, 
major lacunae of these studies include the lack of phytochemi‑
cal standardization of the extract, bioavailability studies, and 
well‑designed studies to evaluate its long‑term toxicity effects. 
Its exact role in primary/secondary coronary prevention needs to 
be investigated. In addition to this, studies to look for the effect 
of arjuna on CYP450 enzymes and its interactions with other 
drugs like statin, aspirin, angiotensin‑converting enzyme (ACE) 
inhibitors, and β‑blocker need to be designed. Increasing the 
awareness regarding its medicinal usage can give a direction to 
the physicians to respond to the challenges in treating cardio‑
vascular diseases.
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